Drug Approval | November 30, 2022
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Subscribe To Our Newsletter & Stay Updated
